Daunorubicin + Cytarabine + Eltrombopag + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Leukaemia
Conditions
Acute Leukaemia
Trial Timeline
Sep 5, 2013 → Jan 25, 2017
NCT ID
NCT01890746About Daunorubicin + Cytarabine + Eltrombopag + Placebo
Daunorubicin + Cytarabine + Eltrombopag + Placebo is a phase 2 stage product being developed by Novartis for Acute Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01890746. Target conditions include Acute Leukaemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01890746 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Leukaemia